Insider buying last 90 days
No open-market insider purchases were filed for ALB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Albemarle's week centered on third-quarter results reported 4 November, with net sales of $1.6B, up 19% year over year, and adjusted EBITDA of $646 million, up 186%, as EBITDA margin expanded to 42%. Energy storage EBITDA surged 351% on higher lithium pricing, while specialties rose 31% on price and volume gains, and the call highlighted $150M+ in cost savings and YTD free cash flow of $1.2 billion. Analyst reaction was mixed on price targets: RBC Capital maintained Outperform but lowered its target to $119 from $129, BMO Capital cut its target to $160 from $175 while keeping Outperform and raising its 2027 EBITDA estimate to $2.1 billion, and a separate consensus of 18 analysts cut the average 12-month target to $138.11 from $141.22 while keeping a Buy rating among 24 covering analysts.
The stock closed at $99.12, down 0.1%, sitting below both its 50-day average of $106.78 and 200-day average of $147.51, with the 50-day also below the 200-day. The GekkoIndex reads 58, placing it in the Neutral zone, down 11.3 over five days. Price sits 21.5% below Gekko Fair Value of $126.22.
Earnings are not due again until 10 February 2027, 92 days out, placing the event outside a typical 20-day holding window. Over the last 90 days, Congress recorded 1 buy and 0 sells, while the last 30 days show 2 unusual options signals with call premium of $1,630,346 against put premium of $7,261. Seasonally, the next 20 trading days have averaged +3.1% over 5 years, rising in 2 of those years, a pattern worth noting alongside the wide gap to fair value.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Albemarle scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $93.53 is below the 50-day ($103.56) and 200-day ($145.66) averages, and the 50-day is below the 200-day.
See the chart62.9, Accumulation
Reading 62.9 is in the Accumulation zone.
See the GekkoIndex20.7% below
Price is 20.7% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 1 unusual options signal.
See smart moneyReports in 87 days
Next report Feb 10, 2027, 87 days away — outside a typical 20-trading-day hold.
See earnings−1.0% on average
From this point in the calendar, the next 20 trading days averaged −1% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Albemarle closed at $93.53 on Nov 13, 2026, −15.2% over the past year, inside a 52-week range of $89.77 to $221.00.
Use the left and right arrow keys to read daily values.
Put ALB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Albemarle produces specialty chemicals that feed into many industrial and consumer products. Its lithium business turns out compounds like carbonate, hydroxide, and chloride, materials that go into batteries powering electric vehicles and electronic devices, plus reagents such as butyllithium used in synthesis for steroids, vitamins, and pharmaceutical work. That same business line supplies cesium for chemical and drug uses, along with zirconium, barium, and titanium destined for pyrotechnic components like airbag triggers, and it backs these products with handling guidance and recycling services for lithium waste streams.
Beyond lithium, Albemarle runs a bromine business making elemental bromine, bromide compounds, and activated carbon products applied in drilling fluids, mercury capture, water treatment, and food handling, alongside amine ingredients used in surfactants and disinfectants. A third business area, catalysts, covers agents for refining steps such as hydroprocessing, isomerization, and alkylation, plus fluid catalytic cracking materials and organometallic compounds. Together these offerings serve sectors like energy storage, refining, electronics, building materials, vehicles, lubricants, drug manufacturing, and agriculture.
The company traces back to 1887 and runs its headquarters out of Charlotte, North Carolina. Albemarle trades on the NYSE under the ticker ALB.
Albemarle’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.9, in the Accumulation zone, up 4.3 points over five sessions.
Up 4.3 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 76 | +0.1% | −0.1% | ||
| Accumulation (current zone) | 248 | −0.8% | −2.6% | ||
| Neutral | 354 | +0.8% | +2.2% | ||
| Distribution | 23 | +0.4% | +7.0% | ||
| Selling | 1 | Too few readings yet | |||
Average ALB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Albemarle trades 20.7% below Gekko Fair Value of $117.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Albemarle shares are worth, recalculated every trading day.
$117.88
Gekko Fair Value, Nov 14, 2026
20.7% Undervalued
At the end of Aug 2026 the price was 14.3% below the estimate.
No open-market insider purchases were filed for Albemarle, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ALB in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 25 |
From congressional disclosures, which report amounts as ranges.
Albemarle has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Oct 17, $495K in unusual premium.
0of the funds Gekko tracks hold ALB.
Albemarle reports on Feb 10, 2027, after the close (87 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 10, 2027
Expected after the close, 87 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $2.58 est $2.53 | $1.55B est $1.52B | +9.1% |
| Aug 5, 2026 | $3.75 est $3.35 | $1.74B est $1.61B | +3.8% |
| May 6, 2026 | $2.95 est $1.31 | $1.43B est $1.34B | +1.8% |
| Feb 11, 2026 | −$0.53 est −$0.42 | $1.43B est $1.35B | −5.7% |
| Nov 5, 2025 | −$0.19 est −$0.86 | $1.31B est $1.28B | +3.2% |
| Jul 30, 2025 | $0.11 est −$0.83 | $1.33B est $1.27B | −5.2% |
| Apr 30, 2025 | −$0.18 est −$0.62 | $1.08B est $1.16B | −0.2% |
| Feb 12, 2025 | −$1.09 est −$0.60 | $1.23B est $1.34B | +4.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Albemarle is $139.35, +49.0% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | DBS | $135 | +44.3% |
| Nov 12 | Bank of America Securities | $120 | +28.3% |
| Nov 11 | Bank of America Securities | $120 | +28.3% |
| Nov 9 | Scotiabank | $165 | +76.4% |
| Nov 9 | Deutsche Bank | $125 | +33.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Albemarle averaged −1.0% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.5% | 4 of 5 |
| Next 10 trading days | −1.3% | 1 of 5 |
| Next 15 trading days | −4.9% | 1 of 5 |
| Next 20 trading days | −1.0% | 2 of 5 |
| Next 30 trading days | −4.5% | 2 of 5 |
For scale, ALB’s typical 20-trading-day move in either direction is about 11.3%.
Albemarle’s market cap is $11.04B, with a P/E ratio of 22.9 and revenue of $6.15B over the last twelve months.
Coverage of Albemarle this week reads positive: 6 positive, 6 neutral and 1 negative headlines.
Albemarle’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LINLinde | Neutral | 4.8% above |
| ECLEcolab | Neutral | 16.6% above |
| APDAir Products and Chemicals | Neutral | 0.5% above |
| DOWDow | Neutral | 23.9% below |
| LYBLyondellBasell Industries | Neutral | 6.5% below |
| WLKWestlake | Accumulation | 22.5% below |
A peer links to its own page where one exists.
Albemarle’s market cap is $11.04B at the Nov 13, 2026 close of $93.53, with 118.0M shares outstanding. The shares trade on a P/E ratio of 22.9.
The consensus analyst 12-month price target for Albemarle is $139.35, +49.0% from the last close. Of the 14 firms that rated the stock in the last 90 days, 11 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Albemarle is undervalued: the Nov 13, 2026 close of $93.53 is 20.7% below Gekko Fair Value of $117.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Albemarle is expected to report on Feb 10, 2027, after the market closes (87 days away). Analysts expect earnings of $1.44 per share on revenue of $1.37B. Albemarle beat the earnings estimate in 6 of its last 8 reports, moving 4.2% on average across the report.
Albemarle’s 52-week high is $221.00 and its 52-week low is $89.77; it closed at $93.53 on Nov 13, 2026, −15.2% over the past year. Over the last five years the shares peaked at $334.55 on Nov 11, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Albemarle over the last 30 days, with $495K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 17, 2026 with $495K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.